Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 280 participants.
Also called NCT03169985
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 280 participants
- Registry
-
NCT03169985
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT03169985. Randomized; double masking; primary purpose treatment. Start 2017-07-12 (actual); primary completion 2027-01-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque
- Acronym
- Rosuzet-IVUS
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day
- Intervention (Drug)
- Rosuvastatin 20 mg orally once a day
- Lead sponsor
- Samsung Medical Center
- Collaborator
- Hanmi Pharmaceutical co., ltd.
Record details
- Record id
cardio:ct-nct03169985- Content hash
36b92efafa391adde7b4f05a80b644a6b4a887d668d7108a3ee895bd02d350c1